3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Colorectal Neoplasms
39
Colonic Neoplasms
10
Neoplasms
8
Stomach Neoplasms
7
Neoplasm Metastasis
4
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Gastrointestinal Neoplasms
3
Cholangiocarcinoma
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Unresectable Metastatic Colorectal Cancer
2
Liver Neoplasms
2
Gastrointestinal Diseases
2
Gallbladder Neoplasms
2
Digestive System Neoplasms
2
Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasm Recurrence, Local
1
Melanoma
1
Lung Neoplasms
1
Intestinal Neoplasms
1
Gastro-enteropancreatic neuroendocrine tumor
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Disease Progression
1
Interventions
pembrolizumab
166
Nivolumab
111
Ipilimumab
93
Dacarbazine
44
trametinib
36
dabrafenib
34
Vemurafenib
33
binimetinib
23
atezolizumab
23
Temozolomide
21
cemiplimab
18
Paclitaxel
18
encorafenib
17
spartalizumab
16
cobimetinib
15
Carboplatin
14
talimogene laherparepvec
13
Cisplatin
13
Cyclophosphamide
12
lenvatinib
10
Pemetrexed
10
Gemcitabine
10
Docetaxel
10
durvalumab
9
Drug Therapy
9
Bevacizumab
9
tremelimumab
8
Injections
8
Albumin-Bound Paclitaxel
8
130-nm albumin-bound paclitaxel
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Melanoma
×
Folfox protocol
×
Clear all
NCT02009449
2024-11-15
IVY
Eli Lilly and Company
Phase 1
Completed
353 enrolled